Date:8/19/2009

------------------------------------------------------------------------- 1,962,399 (9,920) 1,958,923 (16,418) ------------------------------------------------------------------------- (DECREASE)/INCREASE IN CASH 367,961 (1,544,412) (1,157,968) (3,357,903) CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD 972,510 1,428,913 2,498,439 3,242,404 ------------------------------------------------------------------------- END OF PERIOD $ 1,340,471 $ (115,499) $ 1,340,471 $ (115,499) ------------------------------------------------------------------------- ------------------------------------------------------------------------- REPRESENTED BY: Cash 538,006 (234,346) 538,006 (234,346) Cashable guaranteed investment certificates 802,465 118,847 802,465 118,847 ------------------------------------------------------------------------- $ 1,340,471 $ (115,499) $ 1,340,471 $ (115,499) ------------------------------------------------------------------------- ------------------------------------------------------------------------- SUPPLEMENTAL CASH FLOW INFORMATION Interest paid $ 2,276 $ 5,021 $ 5,529 $ 12,535 ------------------------------------------------------------------------- -------------------------------------------------------------------------

About Neovasc Inc.

Neovasc Inc. is a new specialty vascular device company that develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. The company's current products include the Neovasc Reducer(TM), a novel product in development to treat refractory angina, as well as a line of advan
'/>"/>

SOURCE Neovasc Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related medicine news :

1. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
2. Neovasc Inc. Reports Third Quarter Fiscal Year 2008 Financial Results
3. Neovasc Announces Agreement With LeMaitre Vascular for Exclusive Distribution Rights to its Biological Vascular Strips
4. Neovasc Receives CE Mark Approval for Peripatch(TM) Aegis Staple Line Reinforcement Product
5. Neovasc to Raise $2 Million in Non-Brokered Private Placement
6. Neovasc Inc. Reports Year 2008 Financial Results
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Positive Results for Ophthotechs Novel Therapy for Wet AMD - Study of Anti-PDGF and Anti-VEGF Therapy Shows Significant Neovascular Regression and Enhanced Visual Outcome
9. Neovasc Inc. Reports First Quarter 2009 Financial Results
10. Neovasc Inc. Postpones Plans for U.S. Listing to Focus Funds on Commercializing Its Reducer Device for Refractory Angina
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites